Premium
Correction of anemia in a transfusion‐dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade ® , ICL670)
Author(s) -
Di Tucci Anna Angela,
Murru Roberta,
Alberti Daniele,
Rabault Bertrand,
Deplano Simona,
Angelucci Emanuele
Publication year - 2007
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2007.00840.x
Subject(s) - deferasirox , myelofibrosis , medicine , myelodysplastic syndromes , chelation therapy , deferoxamine , deferiprone , anemia , transfusion therapy , blood transfusion , pediatrics , ineffective erythropoiesis , thalassemia , intensive care medicine , erythropoiesis , bone marrow
Transfusional iron overload in patients with chronic anemias can result in multiple organ failure. Experience in the management of iron overload in patients with myelodysplastic syndromes is limited, as many do not receive chelation therapy due to short‐life expectancy and the difficulties associated with the administration of the current reference standard chelator, deferoxamine. There have, however, been some reports of reduced transfusion requirement associated with chelation therapy in patients with myelodysplastic syndromes and myelofibrosis. Here, we discuss a patient with primary myelofibrosis and related transfusion‐dependent anemia who received chelation therapy with the once‐daily oral iron chelator, deferasirox. In addition to the reduced iron levels, the patient demonstrated an unexpected reduction in blood transfusion requirement, ultimately resulting in long‐lasting transfusion‐free survival.